Edition:
United States

ThromboGenics NV (THR.BR)

THR.BR on Brussels Stock Exchange

3.16EUR
26 May 2017
Change (% chg)

-- (--)
Prev Close
€3.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
73,345
52-wk High
€3.88
52-wk Low
€2.50

Select another date:

Thu, May 11 2017

BRIEF-Thrombogenics cash and investments at end of March EUR 73.3 mln

* CASH AND INVESTMENTS WERE EUR 73.3 MILLION AS OF END OF MARCH 2017, COMPARED WITH EUR 80.1 MILLION AT END OF DECEMBER 2016

BRIEF-New Thrombogenics ophthalmic research findings presented at ARVO 2017

* New Thrombogenics ophthalmic research findings presented at ARVO 2017 annual vision research meeting in Baltimore

BRIEF-Thrombogenics achieves important milestone in development of THR-149, novel plasma kallikrein inhibitor for diabetic macular edema

* Achieves important milestone in the development of THR-149, a novel plasma kallikrein inhibitor for diabetic macular edema

BRIEF-Thrombogenics FY net loss widens to 60.3 million euros

* FY operating loss of 60.8 million euros ($65.27 million)versus loss of 38.9 million euros year ago

BRIEF-Thrombogenics cash and cash equivalents at Dec 31 down at 80.1 million euros

* Cash and cash equivalents at Dec 31 80.1 million euros ($85.99 million) versus 101.4 million euros year ago

BRIEF-ThromboGenics enrolls first patients in Phase II clinical study evaluating THR-317 (ANTI-PLGF) for diabetic macular edema (DME)

* The Phase II study will evaluate the safety of 3 intravitreal injections of 2 dose levels of thr-317 (4 mg or 8 mg)

BRIEF-Thrombogenics' Oncurious announces European Commission confirmed orphan medicinal product designation for TB-403 for medulloblastoma

* Oncurious announces European Commission confirmed orphan medicinal product designation for TB-403 for medulloblastoma Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Bioinvent's partner ThromboGenics initiates phase II study

* Bioinvent's collaboration partner ThromboGenics initiates phase II study with the drug candidate THR-317

BRIEF-Thrombogenics enrolls first patients in Phase II clinical study evaluating THR-317 for Diabetic Macular Edema

* Thrombogenics enrolls first patients in Phase II clinical study evaluating THR-317 (Anti-PLGF) for Diabetic Macular Edema (DME)

BRIEF-Thrombogenics transaction settlement provides for 250,000 euro payment - FSMA

* Transaction settlement for Thrombogenics NV provides for payment of amount of 250,000 euros ($264,325) and nominal publication on website of FSMA Source text: http://bit.ly/2iVhVqJ Further company coverage: ($1 = 0.9458 euros) (Gdynia Newsroom)

Select another date:

More From Around the Web